{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:34:47Z","timestamp":1791401687766,"version":"4.3.3"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Rationale\/objectives<\/jats:title>\n                    <jats:p>In advanced Parkinson\u2019s disease (APD), the intermittent dopaminergic delivery of oral L-Dopa contributes to the occurrence of fluctuations and dyskinesia. Continuous dopaminergic delivery through intrajejunal L-Dopa\/Carbidopa intestinal gel (LCIG) is an established therapeutic strategy to manage these motor complications, but its impact on real-life motor performances has never been characterised objectively. This cross-sectional pilot study used wearable sensors to quantitatively evaluate the impact of LCIG on patients\u2019 motor performance in real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material\/methods<\/jats:title>\n                    <jats:p>\n                      Forty-three APD patients, including 15 treated with LCIG infusion (APD\n                      <jats:sub>LCIG<\/jats:sub>\n                      ) and 28 on the best oral dopaminergic therapy (APD\n                      <jats:sub>L-Dopa<\/jats:sub>\n                      ), were evaluated using standardized clinical scales and sensor-based metrics. A validated waist-worn inertial wearable, positioned on the left side, continuously monitored spatiotemporal gait parameters (step length, stride speed, stride fluidity, and cadence) along with freezing of gait (FOG) occurrence, and time spent with dyskinesia. To quantify intra-day variability in motor performance associated with motor fluctuations, the coefficient of variation of all spatiotemporal gait parameters was calculated. Finally, clinical-behavioural correlations were analysed to examine possible relationships between gait features and clinical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Despite comparable clinical and demographic profiles, APD\n                      <jats:sub>LCIG<\/jats:sub>\n                      showed less severe motor fluctuations than APD\n                      <jats:sub>L-Dopa<\/jats:sub>\n                      and exhibited lower intra-day variability in key spatiotemporal gait parameters (step length, stride speed, and stride fluidity). Dyskinesia duration was similar in APD\n                      <jats:sub>LCIG<\/jats:sub>\n                      and APD\n                      <jats:sub>L-Dopa<\/jats:sub>\n                      . Also, mean absolute values of gait parameters and FOG duration did not differ between groups. Stride fluidity, step length, and stride speed were moderately and inversely associated with age and disease severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion\/conclusion<\/jats:title>\n                    <jats:p>LCIG provides a more stable gait pattern than optimized oral dopaminergic therapy in appropriately selected APD patients, as captured by wearable sensors in real-world conditions. This likely reflects more consistent motor control throughout the day due to continuous dopaminergic delivery. By detecting fluctuation-related motor impairment through variability metrics, wearable sensor technology may offer a valuable tool to enhance the clinical management of LCIG, supporting patient selection, medication titration, and the longitudinal monitoring of treatment efficacy and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1812950","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:28:16Z","timestamp":1781497696000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["L-Dopa\/Carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease: real-life mobility insights from wearable sensors"],"prefix":"10.3389","volume":"17","author":[{"given":"Alessandro","family":"Zampogna","sequence":"first","affiliation":[{"name":"Department of Human Neurosciences, Sapienza University of Rome","place":["Rome, Italy"]},{"name":"IRCCS Neuromed Institute","place":["Pozzilli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Borz\u00ec","sequence":"additional","affiliation":[{"name":"Department of Control and Computer Engineering, Politecnico di Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domiziana","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sense Organs (NESMOS), Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Imbalzano","sequence":"additional","affiliation":[{"name":"Department of Neuroscience \u201cRita Levi Montalcini\u201d, University of Turin","place":["Torino, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Patera","sequence":"additional","affiliation":[{"name":"Department of Human Neurosciences, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Falletti","sequence":"additional","affiliation":[{"name":"Department of Human Neurosciences, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Artusi","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Biomedicine, and Movement, University of Verona","place":["Verona, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Campus Bio-Medico","place":["Rome, Italy"]},{"name":"Universit\u00e9 Grenoble Alpes, CNRS, Grenoble INP, LIG Sangria","place":["Grenoble, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Lopiano","sequence":"additional","affiliation":[{"name":"Department of Neuroscience \u201cRita Levi Montalcini\u201d, University of Turin","place":["Torino, Italy"]},{"name":"Neurology 2 Unit, A.O.U Citt\u00e0 della Salute e della Scienza di Torino","place":["Torino, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Olmo","sequence":"additional","affiliation":[{"name":"Department of Control and Computer Engineering, Politecnico di Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Suppa","sequence":"additional","affiliation":[{"name":"Department of Human Neurosciences, Sapienza University of Rome","place":["Rome, Italy"]},{"name":"IRCCS Neuromed Institute","place":["Pozzilli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"106065","DOI":"10.1016\/j.parkreldis.2024.106065","article-title":"\u00abadvanced\u00bb Parkinson\u2019s disease: a review","volume":"123","author":"Aslam","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/mds.28595","article-title":"Intrajejunal infusion of levodopa\/carbidopa for advanced Parkinson\u2019s disease: a systematic review","volume":"36","author":"Tsunemi","year":"2021","journal-title":"Mov Disord"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","article-title":"Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry","volume":"45","author":"Antonini","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.27338","article-title":"Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease","volume":"33","author":"Fernandez","year":"2018","journal-title":"Mov Disord"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1007\/s00415-019-09337-6","article-title":"Motor and non-motor outcomes in patients with advanced Parkinson\u2019s disease treated with levodopa\/carbidopa intestinal gel: final results of the GREENFIELD observational study","volume":"266","author":"Lopiano","year":"2019","journal-title":"J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1756286418759315","DOI":"10.1177\/1756286418759315","article-title":"Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson\u2019s disease","volume":"11","author":"Murata","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fneur.2018.00620","article-title":"Levodopa-carbidopa intestinal gel in Parkinson\u2019s disease: a systematic review and Meta-analysis","volume":"9","author":"Wang","year":"2018","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s12325-017-0571-2","article-title":"An observational study of the effect of levodopa-carbidopa intestinal gel on activities of daily living and quality of life in advanced Parkinson\u2019s disease patients","volume":"34","author":"Kr\u00fcger","year":"2017","journal-title":"Adv Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1007\/s00415-022-11269-7","article-title":"Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson\u2019s disease on levodopa\/carbidopa intestinal gel infusion","volume":"269","author":"Garr\u00ec","year":"2022","journal-title":"J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s0197-2456(02)00320-3","article-title":"Patient compliance with paper and electronic diaries","volume":"24","author":"Stone","year":"2003","journal-title":"Control Clin Trials"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/mds.25628","article-title":"Quantitative wearable sensors for objective assessment of Parkinson\u2019s disease","volume":"28","author":"Maetzler","year":"2013","journal-title":"Mov Disord"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00702-015-1439-8","article-title":"Wearable sensor-based objective assessment of motor symptoms in Parkinson\u2019s disease","volume":"123","author":"Ossig","year":"2016","journal-title":"J Neural Transm"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41531-023-00585-y","article-title":"Overview on wearable sensors for the management of Parkinson\u2019s disease","volume":"9","author":"Moreau","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.3390\/s22124551","article-title":"Objective measurement of walking activity using wearable technologies in people with Parkinson disease: a systematic review","volume":"22","author":"Correno","year":"2022","journal-title":"Sensors"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41531-021-00248-w","article-title":"A real-world study of wearable sensors in Parkinson\u2019s disease","volume":"7","author":"Adams","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/bioengineering11050440","article-title":"Unveiling the unpredictable in Parkinson\u2019s disease: sensor-based monitoring of dyskinesias and freezing of gait in daily life","volume":"11","author":"Zampogna","year":"2024","journal-title":"Bioengineering"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1387477","DOI":"10.3389\/fneur.2024.1387477","article-title":"Wearable sensor devices can automatically identify the ON-OFF status of patients with Parkinson\u2019s disease through an interpretable machine learning model","volume":"15","author":"Wu","year":"2024","journal-title":"Front Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.3390\/s20113247","article-title":"Fifteen years of wireless sensors for balance assessment in neurological disorders","volume":"20","author":"Zampogna","year":"2020","journal-title":"Sensors"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fneur.2017.00406","article-title":"L-DOPA and freezing of gait in Parkinson\u2019s disease: objective assessment through a wearable wireless system","volume":"8","author":"Suppa","year":"2017","journal-title":"Front Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.clinph.2021.06.023","article-title":"Early balance impairment in Parkinson\u2019s disease: evidence from robot-assisted axial rotations","volume":"132","author":"Zampogna","year":"2021","journal-title":"Clin Neurophysiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.3390\/s19235169","article-title":"Long-term home-monitoring sensor technology in patients with Parkinson\u2019s disease-acceptance and adherence","volume":"19","author":"Botros","year":"2019","journal-title":"Sensors"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1435693","DOI":"10.3389\/fdgth.2024.1435693","article-title":"Acceptability of digital health technologies in early Parkinson\u2019s disease: lessons from WATCH-PD","volume":"6","author":"Kangarloo","year":"2024","journal-title":"Front Digit Health"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41531-023-00489-x","article-title":"Symptoms assessment and decision to treat patients with advanced Parkinson\u2019s disease based on wearables data","volume":"9","author":"Virbel-Fleischman","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/14737175.2018.1503948","article-title":"Role of the personal KinetiGraph in the routine clinical assessment of Parkinson\u2019s disease: recommendations from an expert panel","volume":"18","author":"Pahwa","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cns.12807","article-title":"Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry","volume":"24","author":"Johansson","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00415-019-09183-6","article-title":"Sensor-based algorithmic dosing suggestions for oral administration of levodopa\/carbidopa microtablets for Parkinson\u2019s disease: a first experience","volume":"266","author":"Thomas","year":"2019","journal-title":"J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3233\/JPD-160830","article-title":"Wearable sensors for advanced therapy referral in Parkinson\u2019s disease","volume":"6","author":"Heldman","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/jpm12010027","article-title":"Predictive value of ambulatory objective movement measurement for outcomes of levodopa\/carbidopa intestinal gel infusion","volume":"12","author":"Kilin\u00e7alp","year":"2022","journal-title":"J Pers Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.14802\/jmd.20090","article-title":"Parkinson\u2019s kinetigraph in the selection of levodopa-carbidopa intestinal gel for motor fluctuations refractory to deep brain stimulation","volume":"14","author":"Noui","year":"2021","journal-title":"J Mov Disord"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e19068","DOI":"10.2196\/19068","article-title":"Real-life gait performance as a digital biomarker for motor fluctuations: the Parkinson@home validation study","volume":"22","author":"Evers","year":"2020","journal-title":"J Med Internet Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.1038\/s41598-020-61789-3","article-title":"High-resolution motor state detection in Parkinson\u2019s disease using convolutional neural networks","volume":"10","author":"Pfister","year":"2020","journal-title":"Sci Rep"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3233\/JPD-240003","article-title":"Effects of continuous dopaminergic stimulation on Parkinson\u2019s disease gait: a longitudinal prospective study with levodopa intestinal gel infusion","volume":"14","author":"Imbalzano","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00702-023-02656-z","article-title":"Tools and criteria to select patients with advanced Parkinson\u2019s disease for device-aided therapies: a narrative review","volume":"130","author":"Moes","year":"2023","journal-title":"J Neural Transm"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mds.29410","article-title":"Levodopa dose equivalency in Parkinson\u2019s disease: updated systematic review and proposals","volume":"38","author":"Jost","year":"2023","journal-title":"Mov Disord Off J Mov Disord Soc Luglio"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.nrl.2020.10.013","article-title":"Clinical utility of a personalized and long-term monitoring device for Parkinson\u2019s disease in a real clinical practice setting: an expert opinion survey on STAT-ON\u2122","volume":"38","author":"Santos Garc\u00eda","year":"2023","journal-title":"Neurologia"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"912343","DOI":"10.3389\/fneur.2022.912343","article-title":"A new paradigm in Parkinson\u2019s disease evaluation with wearable medical devices: a review of STAT-ONTM","volume":"13","author":"Rodr\u00edguez-Mart\u00edn","year":"2022","journal-title":"Front Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"18971","DOI":"10.3390\/s23218971","article-title":"Four days are enough to provide a reliable daily step count in mild to moderate Parkinson\u2019s disease through a commercial smartwatch","volume":"23","author":"Bianchini","year":"2023","journal-title":"Sensors"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/THC-140882","article-title":"Adapted step length estimators for patients with Parkinson\u2019s disease using a lateral belt worn accelerometer","volume":"23","author":"Sayeed","year":"2015","journal-title":"Technol Health Care Off J Eur Soc Eng Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1109\/EMBC.2012.6346150","article-title":"Dyskinesia and motor state detection in Parkinson\u2019s disease patients with a single movement sensor","volume":"2012","author":"Sam\u00e0","year":"2012","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Int Conf"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.compbiomed.2017.03.020","article-title":"Estimating bradykinesia severity in Parkinson\u2019s disease by analysing gait through a waist-worn sensor","volume":"84","author":"Sam\u00e0","year":"2017","journal-title":"Comput Biol Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e0171764","DOI":"10.1371\/journal.pone.0171764","article-title":"Home detection of freezing of gait using support vector machines through a single waist-worn triaxial accelerometer","volume":"12","author":"Rodr\u00edguez-Mart\u00edn","year":"2017","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e0316052","DOI":"10.1371\/journal.pone.0316052","article-title":"Device-aided therapies (DATs) in Parkinson\u2019s disease (PD). The DATs-PD GETM Spanish registry protocol study","volume":"20","author":"Santos-Garc\u00eda","year":"2025","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/ane.13648","article-title":"Intercountry comparisons of advanced Parkinson\u2019s disease symptoms and management: analysis from the OBSERVE-PD observational study","volume":"146","author":"Fasano","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","article-title":"Access to device-aided therapies in advanced Parkinson\u2019s disease: navigating clinician biases, patient preference, and prognostic uncertainty","volume":"130","author":"Auffret","year":"2023","journal-title":"J Neural Transm"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/JMDH.S27180","article-title":"Lack of information and access to advanced treatment for Parkinson\u2019s disease patients","volume":"4","author":"L\u00f6kk","year":"2011","journal-title":"J Multidiscip Healthc"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","article-title":"Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results","volume":"30","author":"Fernandez","year":"2015","journal-title":"Mov Disord Off J Mov Disord Soc."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3233\/JPD-223295","article-title":"Effects of levodopa-carbidopa intestinal gel on dyskinesia and non-motor symptoms including sleep: results from a meta-analysis with 24-month follow-up","volume":"12","author":"Chaudhuri","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40262-015-0265-3","article-title":"Jejunal infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in Japanese subjects with advanced Parkinson\u2019s disease: pharmacokinetics and pilot efficacy and safety","volume":"54","author":"Othman","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1007\/s12325-021-01747-1","article-title":"The long-term impact of levodopa\/carbidopa intestinal gel on \u2018off\u2019-time in patients with advanced Parkinson\u2019s disease: a systematic review","volume":"38","author":"Antonini","year":"2021","journal-title":"Adv Ther"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/mds.870130310","article-title":"Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson\u2019s disease and Huntington\u2019s disease","volume":"13","author":"Hausdorff","year":"1998","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3988\/jcn.2022.0299","article-title":"Association between baseline gait parameters and future fall risk in patients with de novo Parkinson\u2019s disease: forward versus backward gait","volume":"20","author":"Kwon","year":"2024","journal-title":"J Clin Neurol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e0141694","DOI":"10.1371\/journal.pone.0141694","article-title":"A validated smartphone-based assessment of gait and gait variability in Parkinson\u2019s disease","volume":"10","author":"Ellis","year":"2015","journal-title":"PLoS One"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1096401","DOI":"10.3389\/fneur.2023.1096401","article-title":"Gait and turning characteristics from daily life increase ability to predict future falls in people with Parkinson\u2019s disease","volume":"14","author":"Shah","year":"2023","journal-title":"Front Neurol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41531-022-00383-y","article-title":"Axial impairment and falls in Parkinson\u2019s disease: 15 years of subthalamic deep brain stimulation","volume":"8","author":"Zampogna","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nrneurol.2014.252","article-title":"Axial disability and deep brain stimulation in patients with Parkinson disease","volume":"11","author":"Fasano","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/mds.26269","article-title":"Levodopa is a double-edged sword for balance and gait in people with Parkinson\u2019s disease","volume":"30","author":"Curtze","year":"2015","journal-title":"Mov Disord"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/ene.15558","article-title":"How resistant are levodopa-resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease","volume":"30","author":"Imbalzano","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3390\/biomedicines13112727","article-title":"L-Dopa comparably improves gait and limb movements in Parkinson\u2019s disease: a wearable sensor analysis","volume":"13","author":"Zampogna","year":"2025","journal-title":"Biomedicine"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1179\/1743132811Y.0000000044","article-title":"Gait variability in Parkinson\u2019s disease: influence of walking speed and dopaminergic treatment","volume":"33","author":"Bryant","year":"2011","journal-title":"Neurol Res"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12984-016-0154-5","article-title":"Free-living gait characteristics in ageing and Parkinson\u2019s disease: impact of environment and ambulatory bout length","volume":"13","author":"Del Din","year":"2016","journal-title":"J Neuroeng Rehabil"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1743-0003-2-19","article-title":"Gait variability: methods, modeling and meaning","volume":"2","author":"Hausdorff","year":"2005","journal-title":"J Neuroeng Rehabil"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12889-025-25849-5","article-title":"An updated synthesis of environmental factors influencing mobility and social participation in older adults: results from a scoping review","volume":"26","author":"Paulhus","year":"2025","journal-title":"BMC Public Health"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41746-022-00643-4","article-title":"Identifying and characterising sources of variability in digital outcome measures in Parkinson\u2019s disease","volume":"5","author":"Roussos","year":"2022","journal-title":"NPJ Digit Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S1474-4422(19)30397-7","article-title":"Long-term unsupervised mobility assessment in movement disorders","volume":"19","author":"Warmerdam","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S1474-4422(20)30033-8","article-title":"Wearable-based mobility monitoring: the long road ahead","volume":"19","author":"Fasano","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"21143","DOI":"10.1038\/s41598-021-00543-9","article-title":"A pathophysiological model of gait captures the details of the impairment of pace\/rhythm, variability and asymmetry in parkinsonian patients at distinct stages of the disease","volume":"11","author":"Godi","year":"2021","journal-title":"Sci Rep"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3389\/fnhum.2016.00319","article-title":"Can gait signatures provide quantitative measures for aiding clinical decision-making? A systematic meta-analysis of gait variability behavior in patients with Parkinson\u2019s disease","volume":"10","author":"K\u00f6nig","year":"2016","journal-title":"Front Hum Neurosci"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/mds.26718","article-title":"Free\u2010living monitoring of Parkinson's disease: Lessons from the field","volume":"31","author":"Din","year":"","journal-title":"Movement Disorders"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12984-024-01364-3","article-title":"The impact of anxiety on gait impairments in Parkinson\u2019s disease: insights from sensor-based gait analysis","volume":"21","author":"Zhang","year":"2024","journal-title":"J Neuroeng Rehabil"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1474-4422(19)30044-4","article-title":"Gait impairments in Parkinson\u2019s disease","volume":"18","author":"Mirelman","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1002\/mds.28703","article-title":"Levodopa-carbidopa intestinal gel reduces dyskinesia in Parkinson\u2019s disease in a randomized trial","volume":"36","author":"Freire-Alvarez","year":"2021","journal-title":"Mov Disord"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/mdc3.13068","article-title":"Levodopa\/carbidopa intestinal gel long-term outcome in Parkinson\u2019s disease: focus on dyskinesia","volume":"7","author":"Fabbri","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"70222","DOI":"10.1002\/mdc3.70222","article-title":"Levodopa-carbidopa intestinal gel improves dyskinesia in Parkinson\u2019s disease: post hoc analysis from the COSMOS study","volume":"13","author":"Fasano","year":"","journal-title":"Mov Disord Clin Pract"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s10072-016-2664-0","article-title":"Motor outcomes in patients with advanced Parkinson\u2019s disease treated with levodopa\/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study","volume":"37","author":"Lopiano","year":"2016","journal-title":"Neurol Sci"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.bandc.2009.10.011","article-title":"Impaired awareness of movement disorders in Parkinson\u2019s disease","volume":"72","author":"Amanzio","year":"2010","journal-title":"Brain Cogn"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bandc.2014.06.014","article-title":"Self-unawareness of levodopa induced dyskinesias in patients with Parkinson\u2019s disease","volume":"90","author":"Amanzio","year":"2014","journal-title":"Brain Cogn"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.parkreldis.2016.12.030","article-title":"Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson\u2019s disease","volume":"37","author":"Meloni","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.parkreldis.2019.11.008","article-title":"Complex dyskinesias in Parkinson patients on levodopa\/carbidopa intestinal gel","volume":"69","author":"Marano","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.parkreldis.2015.05.014","article-title":"Long-term response to continuous duodenal infusion of levodopa\/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry","volume":"21","author":"Buongiorno","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/brainsci11070826","article-title":"Management challenges of severe, complex dyskinesia. Data from a large cohort of patients treated with levodopa-carbidopa intestinal gel for advanced Parkinson\u2019s disease","volume":"11","author":"Sz\u00e1sz","year":"2021","journal-title":"Brain Sci"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/mdc3.70143","article-title":"Gender is the main predictor of wearing-off and dyskinesia in levodopa-na\u00efve patients with Parkinson\u2019s disease","volume":"12","author":"Pellecchia","year":"2025","journal-title":"Mov Disord Clin Pract"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40120-024-00687-6","article-title":"Sex differences in Parkinson\u2019s disease: a narrative review","volume":"14","author":"Cattaneo","year":"2025","journal-title":"Neurol Ther"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1111\/ene.14337","article-title":"Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson\u2019s disease","volume":"27","author":"Jung","year":"2020","journal-title":"Eur J Neurol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/ane.13675","article-title":"Adverse effects of levodopa\/carbidopa intrajejunal gel treatment: a single-center long-term follow-up study","volume":"146","author":"Rus","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.parkreldis.2021.10.009","article-title":"Validation and clinical value of the MANAGE-PD tool: a clinician-reported tool to identify Parkinson\u2019s disease patients inadequately controlled on oral medications","volume":"92","author":"Antonini","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"7537924","DOI":"10.1155\/2020\/7537924","article-title":"5-2-1 criteria: a simple screening tool for identifying advanced PD patients who need an optimization of Parkinson\u2019s treatment","volume":"2020","author":"Santos-Garc\u00eda","year":"2020","journal-title":"Parkinson's Dis."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"5522824","DOI":"10.1155\/2024\/5522824","article-title":"Home-based titration with duodenal infusion of levodopa-carbidopa intestinal gel in people with Parkinson\u2019s disease: an observational feasibility study","volume":"2024","author":"Thomsen","year":"2024","journal-title":"Parkinson's Dis."},{"key":"ref90","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s12325-019-01014-4","article-title":"Current practices for outpatient initiation of levodopa-carbidopa intestinal gel for Management of Advanced Parkinson\u2019s disease in the United States","volume":"36","author":"Amjad","year":"2019","journal-title":"Adv Ther"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41531-021-00171-0","article-title":"Gait speed in clinical and daily living assessments in Parkinson\u2019s disease patients: performance versus capacity","volume":"7","author":"Atrsaei","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"e0124763","DOI":"10.1371\/journal.pone.0124763","article-title":"Motor performance assessment in Parkinson\u2019s disease: association between objective in-clinic, objective in-home, and subjective\/semi-objective measures","volume":"10","author":"Toosizadeh","year":"2015","journal-title":"PLoS One"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"416","DOI":"10.14802\/jmd.24167","article-title":"Adjustability of gait speed in clinics and free-living environments for people with Parkinson\u2019s disease","volume":"17","author":"Nishi","year":"2024","journal-title":"J Mov Disord"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/mdc3.12630","article-title":"Implementing levodopa-carbidopa intestinal gel for Parkinson disease: Insights from US practitioners","volume":"5","author":"Burack","year":"2018","journal-title":"Mov Disord Clin Pract"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1812950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:28:22Z","timestamp":1781497702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1812950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":94,"alternative-id":["10.3389\/fneur.2026.1812950"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1812950","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"1812950"}}